Tianjin Lisheng Pharmaceutical Co.,Ltd. (SHE:002393)

Market Cap	5.18B +21.2%
Revenue (ttm)	1.35B +1.0%
Net Income	412.89M +128.6%
EPS	1.34 +130.2%
Shares Out	308.12M
PE Ratio	12.51
Forward PE	n/a
Dividend	1.00 (5.91%)
Ex-Dividend Date	Apr 28, 2026

Volume	3,137,064
Average Volume	6,465,170
Open	21.90
Previous Close	16.91
Day's Range	16.69 - 21.90
52-Week Range	13.43 - 23.98
Beta	0.13
RSI	29.69
Earnings Date	Apr 24, 2026

About SHE:002393

Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers pharmaceutical, traditional Chinese medicine, and antibiotic products in various forms, such as oral solid dosage forms, soft capsules, sterile preparations, and raw materials primarily for cardiovascular and digestive system applications. Its products also include Shoubishan capsules, Jiayindapamide tablets, Sanyu Zhengtong tablets, Xifuni cefdinir dispersible tablets,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1951
• Employees: 1,605
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002393

Financial Performance

In 2025, SHE:002393's revenue was 1.39 billion, an increase of 4.18% compared to the previous year's 1.34 billion. Earnings were 416.28 million, an increase of 125.59%.